Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7:2025:baaf030.
doi: 10.1093/database/baaf030.

CancerPPD2: an updated repository of anticancer peptides and proteins

Milind Chauhan  1 , Amisha Gupta  1 , Ritu Tomer  1 , Gajendra P S Raghava  1
Affiliations

CancerPPD2: an updated repository of anticancer peptides and proteins

Milind Chauhan et al. Database (Oxford). .

Abstract

CancerPPD2 (http://webs.iiitd.edu.in/raghava/cancerppd2/) is an updated version of CancerPPD, developed to maintain comprehensive information about anticancer peptides and proteins. It contains 6521 entries, each entry provides detailed information about an anticancer peptide/protein that include origin of the peptide, cancer cell line, type of cancer, peptide sequence, and structure. These anticancer peptides have been tested against 392 types of cancer cell lines and 28 types of cancer-associated tissues. In addition to natural anticancer peptides, CancerPPD2 contains 781 entries for chemically modified and 3018 entries for N-/C- terminus modified anticancer peptides. Few entries are also linked with 47 clinical studies and have provided the cross reference to Uniprot, DrugBank, and ThPDB2. The possible entries also linked with clinical trials. On average, CancerPPD2 contains around 85% more information than its previous version, CancerPPD. The structures of these anticancer peptides and proteins were either obtained from the Protein Data Bank (PDB) or predicted using PEPstrMOD, I-TASSER, and AlphaFold. A wide range of tools have been integrated into CancerPPD2 for data retrieval and similarity searches. Additionally, we integrated a REST API into this repository to facilitate automatic data retrieval via program. Database URL: https://webs.iiitd.edu.in/raghava/cancerppd2/api/rest.html.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1.
Figure 1.
The figure shows the complete architecture of the database.
Figure 2.
Figure 2.
The figure shows the diversity and distribution of anticancer peptides.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Chiangjong W, Chutipongtanate S, Hongeng S. Anticancer peptide: physicochemical property, functional aspect and trend in clinical application (review). Int J Oncol 2020;57:678–96. doi: 10.3892/ijo.2020.5099 - DOI - PMC - PubMed
    1. Ghaly G, Tallima H, Dabbish E et al. Anti-cancer peptides: status and future prospects. Molecules 2023;28:1148 doi: 10.3390/molecules28031148 - DOI - PMC - PubMed
    1. Jain S, Gupta S, Patiyal S et al. THPdb2: compilation of FDA approved therapeutic peptides and proteins. Drug Discov Today 2024;29:104047. doi: 10.1016/j.drudis.2024.104047 - DOI - PubMed
    1. Vadevoo SMP, Gurung S, Lee H-S et al. Peptides as multifunctional players in cancer therapy. Exp Mol Med 2023;55:1099–109. doi: 10.1038/s12276-023-01016-x - DOI - PMC - PubMed
    1. Vlieghe P, Lisowski V, Martinez J et al. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010;15:40–56. doi: 10.1016/j.drudis.2009.10.009 - DOI - PubMed